IP Verse

Pharmaceutical Composition Of S-Ketamine Hydrochloride - EP2968221

The patent EP2968221 was granted to Janssen Pharmaceutica on Jun 19, 2019. The application was originally filed on Mar 14, 2014 under application number EP14719471A. The patent is currently recorded with a legal status of "Revoked".

EP2968221

JANSSEN PHARMACEUTICA
Application Number
EP14719471A
Filing Date
Mar 14, 2014
Status
Revoked
May 7, 2021
Publication Date
Jun 19, 2019
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

ASPIRE PHARMAMar 18, 2020BROWNADMISSIBLE
SANDOZMar 17, 2020ELKINGTON AND FIFEADMISSIBLE

Patent Citations (9) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
EXAMINATIONWO2014031975
INTERNATIONAL-SEARCH-REPORTDE102007009888
INTERNATIONAL-SEARCH-REPORTWO2007111880
INTERNATIONAL-SEARCH-REPORTWO9423711
OPPOSITIONDE102007009888
OPPOSITIONWO0234293
OPPOSITIONWO2007111880
OPPOSITIONWO2014031975
OPPOSITIONWO9423711

Non-Patent Literature (NPL) Citations (24) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
DESCRIPTION- C.Y. HO ET AL., AM J RHINOL., (2008), vol. 22, no. 2, pages 125 - 9
DESCRIPTION- J. HONG ET AL., CURR OPIN ALLERGY CLIN IMMUNOL., (2009), vol. 9, no. 5, pages 447 - 53
DESCRIPTION- M.G. SONI ET AL., FOOD CHEM TOXICOL., (2001), vol. 39, no. 6, pages 513 - 32
DESCRIPTION- M.G. SONI ET AL., FOOD CHEM TOXICOL., (2005), vol. 43, no. 7, pages 985 - 015
DESCRIPTION- Pharmaceutical Dosage Forms: Disperse Systems, MARCEL DEKKER, INC, vol. 1-2
DESCRIPTION- Pharmaceutical Dosage Forms: Parenteral Medications, vol. 1-2
DESCRIPTION- Pharmaceutical Dosage Forms: Tablets, vol. 1-3
DESCRIPTION- S. OISHI, FOOD CHEM TOXICOL., (2002), vol. 40, no. 12, pages 1807 - 13
DESCRIPTION- The Handbook of Pharmaceutical Excipients, AMERICAN PHARMACEUTICAL ASSOCIATION
INTERNATIONAL-SEARCH-REPORT- HUGE V ET AL, "Effects of low-dose intranasal (S)-ketamine in patients with neuropathic pain", EUROPEAN JOURNAL OF PAIN, SAUNDERS, LONDON, GB, vol. 14, no. 4, ISSN 1090-3801, (20100401), pages 387 - 394, (20090903), XP026985780 [A] 1-18 * paragraph [02.2] *
INTERNATIONAL-SEARCH-REPORT- JOAKIM JOHANSSON ET AL, "Prehospital analgesia using nasal administration of S-ketamine - a case se", SCANDINAVIAN JOURNAL OF TRAUMA, RESUSCITATION AND EMERGENCY MEDICINE, BIOMED CENTRAL LTD, LONDON UK, (20130514), vol. 21, no. 1, doi:10.1186/1757-7241-21-38, ISSN 1757-7241, page 38, XP021151671 [AP] 1-18 * see materials and methods *
OPPOSITION- Alfonso R Gennaro, "Remington: The Science and Practice of Pharmacy", Remington: The Science and Practice of Pharmacy 20th edition, (20000101), pages 1042 - 1043,1047, XP055709659
OPPOSITION- Andrew Wilcock, Robert Twycross, "Therapeutic Reviews: Ketamine", Journal of Pain and Symptom Management, (20110303), vol. 41, pages 640 - 649, XP055718829
OPPOSITION- Anonymous, "Design of dosage forms", Aulton's Pharmaceutics. The design and manufacture of medicines, Churchill Livingstone Elsevier, (20070101), pages 8,368 - 369,616-620, XP055455526
OPPOSITION- Anonymous, "European Pharmacopoeia 7th edition", European Pharmacopoeia 7th edition, (20100101), pages 1 - 11, XP055709645
OPPOSITION- Anonymous, "GUIDELINE ON EXCIPIENTS IN THE DOSSIER FOR APPLICATION FOR MARKETING AUTHORISATION OF A MEDICINAL PRODUCT", European Medicines Agency Inspections COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP), (20070619), pages 1 - 124, European Medicines Agency Inspections COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP), URL: http://academy.gmp-compliance.org/guidemgr/files/39695106ENFIN.PDF, (20200629), XP055709642
OPPOSITION- Anonymous, "Ketalar 10 mg/ml Injection - Summary of Product Characteristics (SmPC) - (emc)", (201912), page 7pp, URL: https://www.medicines.org.uk/emc/product/2231/smpc, XP055718839
OPPOSITION- Anonymous, "Ketanest® S Fachinformation", Pfizer, (201901), pages 1 - 6, URL: https://www.pfizer.de/medikamente-produkte/rezeptpflichtige-medikamente/pfizer-produkte/detailansicht/ketanestR-s, XP055718842
OPPOSITION- C. BITTER, "TRANSMUCOSAL NASAL DRUG DELIVERY Pharmacokinetics and Pharmacodynamics of Nasally Applied Esketamine", Doctoral Thesis, (20110000), pages 1 - 208
OPPOSITION- Daniel Limmer, Remington: The Science and Practice of Pharmacy, 20th Edition, Lippincott Williams & Wilkins, (2000), page 1398, XP055718835
OPPOSITION- Gocmen Sedef; Buyukkocak Unase; Caglayan Osman, "In Vitro Investigation of the Antibacterial Effect of Ketamine", UPSALA JOURNAL OF MEDICAL SCIENCES., UPSALA MEDICAL SOCIETY., SE, SE, (20080101), vol. 113, no. 1, ISSN 0300-9734, pages 39 - 45, XP009148570
OPPOSITION- M E Aulton, PHARMACEUTICS: THE SCIENCE OF DOSAGE FORM DESIGN, Churchill Livingstone, (19880000), pages 254-258, 262-267 ; 485 - 490, ISBN 0-443-03643-8, XP055718826
OPPOSITION- Raymond C Rowe, Et Al, "Citric Acid Monohydrate", Handbook of Pharmaceutical Excipients 6th edition, Apha, (20090101), pages 181 - 250,648,649, XP055709637
OPPOSITION- Zekine Begec, Et Al, "The antimicrobial effects of ketamine combined with propofol: An in vitro study", Brazilian Journal of Anesthesiology (English Edition), (20131101), vol. 63, no. 6, doi:10.1016/j.bjane.2012.09.004, ISSN 0104-0014, pages 461 - 465, XP055709649

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents